SCHEDULE 13G/A: Fairmount Funds Management Discloses 6.6% Stake in Enliven Therapeutics
Schedule 13G Amendment
Fairmount Funds Management LLC and its affiliates have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 6.6% in Enliven Therapeutics, Inc.'s common stock as of December 31, 2024.
Summary
- Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Harwin, and Tomas Kiselak (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G.
- The filing reports a beneficial ownership of 3,202,798 shares of Enliven Therapeutics, Inc. Common Stock.
- This ownership represents 6.6% of the Issuer's outstanding Common Stock.
- The percentage calculation is based on 48,859,166 shares of Common Stock outstanding as of November 1, 2024, as disclosed in the Issuer's Form 10-Q filed on November 13, 2024.
- Fairmount Funds Management LLC serves as the investment adviser for Fairmount Healthcare Fund II L.P. and holds shared voting and dispositive power over the reported shares.
- Peter Harwin and Tomas Kiselak, as managing members of Fairmount Funds Management LLC, are also deemed beneficial owners with shared voting and dispositive power.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently suggest a positive or negative sentiment. It is a neutral regulatory filing.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic outlook.
Industry Context
This filing is a routine disclosure by an institutional investor, Fairmount Funds Management, regarding its passive ownership stake in Enliven Therapeutics, a biotechnology company. Such filings provide transparency on significant shareholder positions, which can be of interest to other investors tracking institutional sentiment and ownership concentration within the biotech sector.
Stakeholder Impact
- Shareholders: Provides transparency on a significant institutional holding, which can influence market perception and liquidity.
- Management: Awareness of a large, passive shareholder, though the filing explicitly states no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 2023-04-27 | Original Schedule 13G filing date. |
| 2024-02-14 | Amendment No. 1 to Schedule 13G filing date. |
| 2024-11-01 | Date as of which 48,859,166 shares of Issuer's Common Stock were outstanding, as per Form 10-Q. |
| 2024-11-13 | Date Enliven Therapeutics, Inc. filed its Form 10-Q disclosing shares outstanding. |
| 2024-11-14 | Amendment No. 2 to Schedule 13G filing date. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end). |
| 2025-02-14 | Filing date of Amendment No. 3 to Schedule 13G. |
Keywords
Enliven Therapeutics, Fairmount Funds Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Healthcare Fund
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.